---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007622"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:40:44.531150+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway

## Summary
- Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.
- UDENYCA net sales $42.7M, up 18% QoQ and 63% YoY; LOQTORZI launch sales $2.0M; CIMERLI divested for $187.8M cash.
- Non-GAAP net loss $35.8M (-$0.32 per share), improved from non-GAAP net loss $59.5M in Q1 2023.
- New debt and royalty financing replaces $75M term loan; debt maturity extended to May 2029.
- Entered partnership with CRI and ENB Therapeutics to study toripalimab in ovarian cancer.

## SEC filing metadata
- accession: 0001558370-24-007622
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/0001558370-24-007622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/chrs-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007622
- JSON: https://secwatch.observer/filing/0001558370-24-007622.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007622.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported the quarter ended March 31, 2024 results: revenue $77.1 million, net income $102.9 million, EPS $0.83 per share on a diluted basis.
  - Period: the quarter ended March 31, 2024
  - Revenue: $77.1 million
  - Net income: $102.9 million
  - EPS: $0.83 per share on a diluted basis
  - Result: reported results
  source text: reference in such a filing. --- EX-99.1 (EX-99.1) --- ​ ​ ​ Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update ​ – Net revenue of $77.1 million in Q1 2024 – ​ – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – ​ – New debt and royalty financing replaces $75 million term loan, with debt
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/0001558370-24-007622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.